Clinical Trial Update: TMLI and Alemtuzumab for Treatment of Sickle Cell Disease [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating total marrow irradiation with alemtuzumab conditioning for sickle cell disease, sponsored by City of Hope Medical Center; currently act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Sickle Cell Disease | Phase 1 | Status: ACTIVE_NOT_RECRUITING